Weight-loss drug semaglutide extends life in elderly female mice
Pharmacology News

Weight-loss drug semaglutide extends life in elderly female mice

Neuronix 04 Sep, 2026 2 min read

Old female mice given daily semaglutide, the drug in Ozempic and Wegovy, lived a median of 92 days longer than untreated mice, a University of California, Berkeley team reports in Nature on 2 September.

GLP-1 drugs such as semaglutide have shown benefits that reach well beyond weight and blood sugar control. The study offers one possible explanation: in mice, at least, the drug seems to slow aging itself.

Yufan Feng, Danica Chen and colleagues began the injections in 20-month-old mice of a standard lab strain, an age at which the animals are already in decline. After three months, treated mice outperformed controls on a rotating rod, an inverted wire screen and a treadmill run to exhaustion, and did better in a maze test of spatial memory. Stem cells in their bone marrow and brain showed fewer signs of age, and gene activity tied to inflammation and other hallmarks of aging fell.

Mice kept on the drug for the rest of their lives reached a median lifespan of 834 days, against 742 days for mice given saline, a gain of about 12%.

Drug versus diet

Semaglutide makes animals eat less, and eating less is the best-known way to extend life in lab animals. So the team ran a five-month comparison with mice whose food was cut by 24%, matched to the feeding pattern of the treated group. Both groups held on to much of their physical function. The semaglutide mice went further, beating their own starting scores for exploration, spatial memory and blood sugar control, and their metabolic rate stayed largely steady while that of the dieting mice dropped.

"These differences point to the possibility that GLP-1 drugs tap into a biological pathway independent of calorie restriction," says Chen. What that pathway is remains unknown.

The work used only females of one inbred strain, chosen partly because males fight when housed together for long studies. It does not show that the drug lengthens human lives, and the researchers say clinical studies would be needed to test that. The project was funded by the US National Institute on Aging.

Sources: UC Berkeley Department of Metabolic Biology & Nutrition; Nature (original study). Image: Understanding Animal Research/Wikimedia Commons (CC BY-SA 4.0).

semaglutide semaglutide lifespan Ozempic and aging GLP-1 drugs life extension in mice calorie restriction anti-aging drugs weight loss drug longevity research aging biology

Share This Post:

Like (Please login to like articles)

Comments

Please login to leave a comment Sign in

Related Articles